We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results?
Read MoreHide Full Article
Key Takeaways
{\"0\":\"Cencora\'s U.S. Healthcare Solutions segment continues to drive growth, led by strong specialty demand.\",\"1\":\"GLP-1 revenue rose 36% year over year but dipped 10% sequentially due to seasonal trends.\",\"2\":\"International segment lags, with lowered outlook tied to weak clinical logistics and consulting demand.\"}
Cencora (COR - Free Report) is slated to report third-quarter fiscal 2025 results on Aug. 6, before market open.
In the last reported quarter, the company delivered an earnings surprise of 8.33%. COR’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6%.
Cencora’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $80.33 billion, up 8.2% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $3.78 per share, indicating an improvement of 13.2% from the prior-year quarter’s figure.
Factors to Consider Before COR Reports
Cencora has entered the fiscal third quarter with solid momentum, mainly driven by its U.S. Healthcare Solutions segment. This segment delivered $68.3 billion in revenues in the second quarter, marking an 11% year-over-year increase. Growth was supported by strong demand for specialty medicines, including GLP-1 therapies, and solid performance across physician practices and health systems. The company has already raised its full-year operating income outlook for this segment, and the fiscal third quarter is likely to reflect continued benefit from this strong first-half performance.
Specialty products remain a key growth area. In the fiscal second quarter, operating income in the U.S. segment rose 23%, helped by expanding use of biosimilars and increased services for specialty providers. Although GLP-1 revenue was up 36 percent year over year, it declined 10% compared to the prior quarter due to seasonal factors and market normalization. In the fiscal third quarter, specialty volumes are likely to remain strong, and the overall product mix is expected to support healthy profit margins, even if revenue growth moderates slightly from earlier levels.
Our model expects revenues for this segment to be $73.1 billion. Adjusted operating income is estimated to be $833.7 million.
Performance in the International Healthcare Solutions segment is likely to remain more modest in the fiscal third quarter. This segment generated $7.2 billion in revenue last quarter, growing 1% on a reported basis and 6% in constant currency. However, operating income declined 17%, mostly due to continued weakness in clinical trial logistics and lower demand for consulting projects. The company has lowered full-year expectations for this segment, and fiscal third-quarter results are likely to reflect ongoing softness, particularly in higher-margin service lines.
COR’s acquisition of Retina Consultants of America (RCA) is expected to play a growing role in the company’s margin profile. While RCA had little effect on overall revenue due to internal adjustments, it contributed positively to both gross and operating margins. In the fiscal third quarter, RCA’s impact is likely to become more visible as integration progresses. This move also supports Cencora’s broader strategy to expand in medical services and deepen relationships with specialty care providers. Over time, these investments are expected to strengthen the company’s market position and long-term earnings potential.
Our model expects the segment’s adjusted operating income and revenues to be $189.3 million and $7.3 billion, respectively.
Our proven model does not predict an earnings beat for Cencora this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Cencora currently has a Zacks Rank #2.
Stocks Worth a Look
Cardinal Health, Inc. (CAH - Free Report) , CorMedix Inc. (CRMD - Free Report) and McKesson Corporation (MCK - Free Report) are a few medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
Image: Bigstock
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results?
Key Takeaways
Cencora (COR - Free Report) is slated to report third-quarter fiscal 2025 results on Aug. 6, before market open.
In the last reported quarter, the company delivered an earnings surprise of 8.33%. COR’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6%.
Cencora’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $80.33 billion, up 8.2% from the prior-year quarter’s level. The consensus mark for earnings is pinned at $3.78 per share, indicating an improvement of 13.2% from the prior-year quarter’s figure.
Factors to Consider Before COR Reports
Cencora has entered the fiscal third quarter with solid momentum, mainly driven by its U.S. Healthcare Solutions segment. This segment delivered $68.3 billion in revenues in the second quarter, marking an 11% year-over-year increase. Growth was supported by strong demand for specialty medicines, including GLP-1 therapies, and solid performance across physician practices and health systems. The company has already raised its full-year operating income outlook for this segment, and the fiscal third quarter is likely to reflect continued benefit from this strong first-half performance.
Specialty products remain a key growth area. In the fiscal second quarter, operating income in the U.S. segment rose 23%, helped by expanding use of biosimilars and increased services for specialty providers. Although GLP-1 revenue was up 36 percent year over year, it declined 10% compared to the prior quarter due to seasonal factors and market normalization. In the fiscal third quarter, specialty volumes are likely to remain strong, and the overall product mix is expected to support healthy profit margins, even if revenue growth moderates slightly from earlier levels.
Our model expects revenues for this segment to be $73.1 billion. Adjusted operating income is estimated to be $833.7 million.
Performance in the International Healthcare Solutions segment is likely to remain more modest in the fiscal third quarter. This segment generated $7.2 billion in revenue last quarter, growing 1% on a reported basis and 6% in constant currency. However, operating income declined 17%, mostly due to continued weakness in clinical trial logistics and lower demand for consulting projects. The company has lowered full-year expectations for this segment, and fiscal third-quarter results are likely to reflect ongoing softness, particularly in higher-margin service lines.
COR’s acquisition of Retina Consultants of America (RCA) is expected to play a growing role in the company’s margin profile. While RCA had little effect on overall revenue due to internal adjustments, it contributed positively to both gross and operating margins. In the fiscal third quarter, RCA’s impact is likely to become more visible as integration progresses. This move also supports Cencora’s broader strategy to expand in medical services and deepen relationships with specialty care providers. Over time, these investments are expected to strengthen the company’s market position and long-term earnings potential.
Our model expects the segment’s adjusted operating income and revenues to be $189.3 million and $7.3 billion, respectively.
Cencora, Inc. Price and EPS Surprise
Cencora, Inc. price-eps-surprise | Cencora, Inc. Quote
Earnings Beat Unlikely
Our proven model does not predict an earnings beat for Cencora this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Cencora currently has a Zacks Rank #2.
Stocks Worth a Look
Cardinal Health, Inc. (CAH - Free Report) , CorMedix Inc. (CRMD - Free Report) and McKesson Corporation (MCK - Free Report) are a few medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
Cardinal Health has an Earnings ESP of +0.72% and a Zacks Rank of 2. CAH has an estimated long-term growth rate of 10.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cardinal Health’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.3%.
CorMedix has an Earnings ESP of +27.12% and is a Zacks Rank #1 stock. CRMD has an estimated growth rate of 70.1% for 2026.
CorMedix’s earnings surpassed estimates in all the trailing four quarters, with the average surprise being 25.8%.
McKesson has an Earnings ESP of +0.14% and a Zacks Rank of 2. MCK has an estimated long-term growth rate of 13.3%.
McKesson’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.9%.